RNS Number : 7725Z
Valereum PLC
17 May 2023

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR")

17 May 2023

Valereum Plc
("**Valereum**" or the "**Company**")

Issue of Shares

Valereum Plc, the Gibraltar technology group, is pleased to announce that it will be issuing a total of 3,690,575 new ordinary shares of 0.1 pence each (the "Ordinary Shares") at a price of 4.3289 pence per share which equates to £159,760 (US$200,000), following the conversion notice received by the Company under the terms of the funding facility announced on 31st January 2022. This brings the outstanding balance down to US$1m.

Application will be made for the listing of the new Ordinary Shares, which will rank *pari passu* with the existing Ordinary Shares in issue, to be admitted to trading on the AQSE Growth Market ("Admission"). Dealings are expected to commence on or about 23rd May 2023 and the issue is subject only to Admission.

Following the issuance of shares, the Company's total issued and voting share capital upon Admission will consist of 93,223,699 Ordinary Shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, securities of the Company.

The Directors of the Company accept responsibility for the contents of this announcement.

END

Enquiries:

Valereum Plc
Richard Poulden, Chairman
Tel: +971 4584 6284

AQSE Corporate Adviser

First Sentinel Corporate Finance
Brian Stockbridge
Tel: +44 (0) 7876 888 011

Investor Relations
J&H Communications Limited
George Hudson
Tel: +44 (0)7803 603130
george@j-hcommunications.com

For more information, please visit the Company's website at valereum.gi

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXMZGMKDNGGFZM